AbbVie (ABBV) 10-Q7 Aug 182018 Q2 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2018	Jul. 31, 2018
Document and Entity Information
Entity Registrant Name	AbbVie Inc.
Entity Central Index Key	1,551,152
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		1,514,272,698
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Net revenues	$ 8,278	$ 6,944	$ 16,212	$ 13,482
Cost of products sold	1,934	1,529	3,861	3,145
Selling, general and administrative	1,760	1,509	3,551	2,882
Research and development	1,322	1,229	2,566	2,371
Acquired in-process research and development	0	15	69	15
Other expense	500	0	500	0
Total operating costs and expenses	5,516	4,282	10,547	8,413
Operating earnings	2,762	2,662	5,665	5,069
Interest expense, net	272	253	523	500
Net foreign exchange loss	8	6	16	19
Other expense, net	470	50	317	111
Earnings before income tax expense	2,012	2,353	4,809	4,439
Income tax expense	29	438	43	813
Net earnings	$ 1,983	$ 1,915	$ 4,766	$ 3,626
Per share data
Basic earnings per share (in dollars per share)	$ 1.26	$ 1.20	$ 3	$ 2.26
Diluted earnings per share (in dollars per share)	1.26	1.19	2.99	2.25
Cash dividends declared per common share (in dollars per share)	$ 0.96	$ 0.64	$ 1.92	$ 1.28
Weighted-average basic shares outstanding (in shares)	1,568	1,595	1,579	1,595
Weighted-average diluted shares outstanding (in shares)	1,572	1,600	1,584	1,602

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net earnings	$ 1,983	$ 1,915	$ 4,766	$ 3,626
Foreign currency translation adjustments, net of tax expense (benefit) of $(16) for the three months and $(19) for the six months ended June 30, 2018 and $33 for the three months and $33 for the six months ended June 30, 2017	(469)	249	(280)	419
Pension and post-employment benefits, net of tax expense (benefit) of $7 for the three months and $16 for the six months ended June 30, 2018 and $7 for the three months and $15 for the six months ended June 30, 2017	49	2	71	13
Marketable security activities, net of tax expense (benefit) of $— for the three months and $— for the six months ended June 30, 2018 and $3 for the three months and $2 for the six months ended June 30, 2017	5	18	(2)	10
Other comprehensive income (loss)	(9)	(6)	88	38
Comprehensive income	1,974	1,909	4,854	3,664
Net investment hedging activities, net of tax expense (benefit) of $61 for the three months and $31 for the six months ended June 30, 2018 and $(86) for the three months and $(122) for the six months ended June 30, 2017
Hedging activities, net of tax expense (benefit)	209	(153)	105	(217)
Cash flow hedging activities, net of tax expense (benefit) of $18 for the three months and $17 for the six months ended June 30, 2018 and $(2) for the three months and $(15) for the six months ended June 30, 2017
Hedging activities, net of tax expense (benefit)	$ 197	$ (122)	$ 194	$ (187)

Condensed Consolidated Stateme4

Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Foreign currency translation adjustments, tax expense (benefit)	$ (16)	$ 33	$ (19)	$ 33
Pension and post-employment benefits, tax expense (benefit)	7	7	16	15
Unrealized (losses) gains on marketable equity securities, tax (benefit) expense	0	3	0	2
Net Investment Hedges
Hedging activities, tax (benefit) expense	61	(86)	31	(122)
Cash Flow Hedges
Hedging activities, tax (benefit) expense	$ 18	$ (2)	$ 17	$ (15)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash and equivalents	$ 3,547	$ 9,303
Short-term investments	196	486
Accounts receivable, net	5,793	5,088
Inventories	1,580	1,605
Prepaid expenses and other	2,729	4,741
Total current assets	13,845	21,223
Investments	1,505	2,090
Property and equipment, net	2,787	2,803
Intangible assets, net	26,903	27,559
Goodwill	15,692	15,785
Other assets	909	1,326
Total assets	61,641	70,786
Current liabilities
Short-term borrowings	3,511	400
Current portion of long-term debt and lease obligations	3,019	6,015
Accounts payable and accrued liabilities	10,694	10,226
Total current liabilities	17,224	16,641
Long-term debt and lease obligations	30,579	30,953
Deferred income taxes	1,670	2,490
Other long-term liabilities	15,543	15,605
Commitments and contingencies
Stockholders’ equity (deficit)
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,775,689,133 shares issued as of June 30, 2018 and 1,768,738,550 as of December 31, 2017	18	18
Common stock held in treasury, at cost, 261,561,225 shares as of June 30, 2018 and 176,607,525 as of December 31, 2017	(20,845)	(11,923)
Additional paid-in capital	14,596	14,270
Retained earnings	5,495	5,459
Accumulated other comprehensive loss	(2,639)	(2,727)
Total stockholders’ equity (deficit)	(3,375)	5,097
Total liabilities and equity	$ 61,641	$ 70,786

Condensed Consolidated Balance6

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,775,689,133	1,768,738,550
Common stock held in treasury, at cost (in shares)	261,561,225	176,607,525

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities
Net earnings	$ 4,766	$ 3,626
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	234	213
Amortization of intangible assets	654	540
Change in fair value of contingent consideration liabilities	337	146
Stock-based compensation	276	217
Upfront costs and milestones related to collaborations	656	53
Other, net	118	134
Changes in operating assets and liabilities:
Accounts receivable	(805)	(167)
Inventories	(191)	1
Prepaid expenses and other assets	(546)	(128)
Accounts payable and other liabilities	12	(530)
Cash flows from operating activities	5,511	4,105
Cash flows from investing activities
Acquisitions and investments	(401)	(100)
Acquisitions of property and equipment	(233)	(221)
Purchases of investment securities	(637)	(1,391)
Sales and maturities of investment securities	1,511	1,346
Cash flows from investing activities	240	(366)
Cash flows from financing activities
Net change in commercial paper borrowings	111	23
Proceeds from issuance of other short-term borrowings	3,000	0
Repayments of long-term debt and lease obligations	(3,013)	(13)
Dividends paid	(2,668)	(2,051)
Purchases of treasury stock	(8,947)	(900)
Proceeds from the exercise of stock options	64	149
Payments of contingent consideration liabilities	(39)	0
Other, net	5	18
Cash flows from financing activities	(11,487)	(2,774)
Effect of exchange rate changes on cash and equivalents	(20)	23
Net change in cash and equivalents	(5,756)	988
Cash and equivalents, beginning of period	9,303	5,100
Cash and equivalents, end of period	$ 3,547	$ 6,088

Basis of Presentation

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation Basis of Historical Presentation The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2017 . It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU No. 2014-09 In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Summary and Amendments That Create Revenue from Contracts with Customers (Topic 606) and Other Assets and Deferred Costs - Contracts with Customers (Subtopic 340-40) . The amendments in this standard superseded most existing revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. AbbVie adopted the standard in the first quarter of 2018 using the modified retrospective method. Results for reporting periods beginning after December 31, 2017 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie’s historical accounting. The cumulative effect of initially applying the new revenue standard was recognized as an adjustment to the opening balance of retained earnings as of January 1, 2018. There were no significant changes to the amounts or timing of revenue recognition for product sales, the company's primary revenue stream. For certain licensing arrangements where revenue was previously deferred and recognized over time, revenue is now recognized at the point in time when the license is granted. Additionally, for certain contract manufacturing arrangements where revenue was previously recognized at a point in time at the end of the manufacturing process, revenue is now recognized over time throughout the manufacturing process. Under the new standard, on January 1, 2018, the company recognized a cumulative-effect adjustment to retained earnings primarily related to certain deferred license revenues that were originally expected to be recognized through early 2020. The adjustment to the condensed consolidated balance sheet included: (i) a $42 million increase to prepaid expenses and other; (ii) a $39 million decrease to inventories; (iii) a $57 million decrease to accounts payable and accrued liabilities; (iv) a $75 million decrease to other long-term liabilities; (v) a $22 million increase to deferred income taxes; and (vi) a $124 million increase to retained earnings. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant. The impact of adoption on the company’s condensed consolidated statement of earnings for the three and six months ended June 30, 2018 was as follows: Three months ended Six months ended (in millions, except per share data) As Reported Balances Without Adoption of ASU 2014-09 Effect of Change Higher/(Lower) As Reported Balances Without Adoption of ASU 2014-09 Effect of Change Higher/(Lower) Net revenues $ 8,278 $ 8,291 $ (13 ) $ 16,212 $ 16,182 $ 30 Cost of products sold 1,934 1,939 (5 ) 3,861 3,845 16 Income tax expense 29 29 — 43 36 7 Net earnings 1,983 1,991 (8 ) 4,766 4,759 7 Diluted earnings per share $ 1.26 $ 1.26 $ — $ 2.99 $ 2.99 $ — As of June 30, 2018 , due to the impact of the adoption of ASU 2014-09, prepaid expenses and other were $101 million higher, inventories were $54 million lower, accounts payable and accrued liabilities were $46 million lower, other long-term liabilities were $46 million lower, deferred income taxes were $16 million higher and retained earnings were $131 million higher on the company’s condensed consolidated balance sheet than they would have been had ASU 2014-09 not been adopted. Other impacts to the condensed consolidated balance sheet were insignificant. ASU No. 2016-01 In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities . The standard requires several targeted changes including that equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) be measured at fair value with changes in fair value recognized in net earnings. AbbVie adopted the standard in the first quarter of 2018. The adoption did not impact the accounting for AbbVie's investments in debt securities and did not have a material impact on the company's consolidated financial statements. ASU No. 2016-16 In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740) . The standard requires entities to recognize the income tax consequences of an intercompany transfer of an asset other than inventory when the transfer occurs. Under previous U.S. GAAP, the income tax consequences of these intercompany asset transfers were deferred until the asset was sold to a third party or otherwise recovered through use. AbbVie adopted the standard in the first quarter of 2018 using the modified retrospective method. As a result, on January 1, 2018, the company recorded a cumulative-effect adjustment to its condensed consolidated balance sheet that included a $1.9 billion decrease to retained earnings, a $1.4 billion decrease to prepaid expenses and other and a $0.5 billion decrease to other assets. ASU No. 2017-07 In March 2017, the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost . The standard requires that an employer continue to report the service cost component of net periodic benefit cost in the same income statement line item or items as other employee compensation costs arising from services rendered during the period. The other components of net periodic benefit cost are required to be presented separately outside of income from operations and are not eligible for capitalization. AbbVie adopted the standard in the first quarter of 2018 and applied the income statement classification provisions of this standard retrospectively. As a result, the company reclassified income of $12 million from operating earnings to non-operating income for the three months and $24 million for the six months ended June 30, 2017 . Additionally, the company recorded approximately $14 million of non-operating income for the three months and $18 million for the six months ended June 30, 2018 which would have been recorded in operating earnings under the previous guidance. ASU No. 2017-12 In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The standard simplifies the application of hedge accounting and more closely aligns the accounting with an entity’s risk management activities. AbbVie elected to early adopt the standard in the first quarter of 2018. The adoption did not have a material impact on the company's consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted ASU No. 2016-02 In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . The standard outlines a comprehensive lease accounting model that supersedes the current lease guidance and requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new standard must be adopted using the modified retrospective approach and will be effective for AbbVie starting with the first quarter of 2019, with early adoption permitted. AbbVie will adopt the standard effective in the first quarter of 2019 and is currently assessing the impact of adopting this guidance on its consolidated financial statements and related disclosures. AbbVie does not expect the adoption will have a material impact on its consolidated statement of earnings. However, the new standard will require AbbVie to establish liabilities and corresponding right-of-use assets on its consolidated balance sheet for operating leases that exist as of the January 1, 2019 adoption date. ASU No. 2016-13 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) . The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. Early adoption beginning in the first quarter of 2019 is permitted. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact and timing of adopting this guidance on its consolidated financial statements. ASU No. 2018-02 In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act. The standard will be effective for AbbVie starting with the first quarter of 2019, with early adoption permitted. AbbVie is currently assessing the impact and timing of adopting this guidance on its consolidated financial statements.

Revenue Recognition

Revenue Recognition	6 Months Ended
Revenue Recognition	Jun. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition AbbVie recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration AbbVie expects to be entitled to in exchange for those goods or services. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue. AbbVie generates revenue primarily from product sales. For the majority of sales, the company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. The company recognizes shipping and handling costs as an expense in cost of products sold when the company transfers control to the customer. Payment terms vary depending on the type and location of the customer, are based on customary commercial terms and are generally less than one year. AbbVie does not adjust revenue for the effects of a significant financing component for contracts where AbbVie expects the period between the transfer of the good or service and collection to be one year or less. Discounts, rebates, sales incentives to customers, returns and certain other adjustments are accounted for as variable consideration. Provisions for variable consideration are based on current pricing, executed contracts, government pricing legislation and historical data and are provided for in the period the related revenues are recorded. Rebate amounts are typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, factors used in the calculation of the accrual include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant. Sales incentives to customers are insignificant. In addition to revenue from contracts with customers, the company also recognizes certain collaboration revenues. See Note 6 for additional information related to the collaboration with Janssen Biotech, Inc. Additionally, see Note 14 for disaggregation of revenue by product and geography.

Supplemental Financial Informat

Supplemental Financial Information	6 Months Ended
Supplemental Financial Information	Jun. 30, 2018
Supplemental Financial Information
Supplemental Financial Information	Supplemental Financial Information Interest Expense, Net Three months ended Six months ended (in millions) 2018 2017 2018 2017 Interest expense $ 320 $ 284 $ 629 $ 557 Interest income (48 ) (31 ) (106 ) (57 ) Interest expense, net $ 272 $ 253 $ 523 $ 500 Inventories (in millions) June 30, 2018 December 31, 2017 Finished goods $ 465 $ 610 Work-in-process 924 822 Raw materials 191 173 Inventories $ 1,580 $ 1,605 Property and Equipment (in millions) June 30, 2018 December 31, 2017 Property and equipment, gross $ 8,214 $ 8,071 Accumulated depreciation (5,427 ) (5,268 ) Property and equipment, net $ 2,787 $ 2,803 Depreciation expense was $119 million for the three months and $234 million for the six months ended June 30, 2018 and $110 million for the three months and $213 million for the six months ended June 30, 2017 .

Earnings Per Share

Earnings Per Share	6 Months Ended
Earnings Per Share	Jun. 30, 2018
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share AbbVie grants certain restricted stock awards (RSAs) and restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method: Three months ended Six months ended (in millions, except per share data) 2018 2017 2018 2017 Basic EPS Net earnings $ 1,983 $ 1,915 $ 4,766 $ 3,626 Earnings allocated to participating securities 10 9 22 18 Earnings available to common shareholders $ 1,973 $ 1,906 $ 4,744 $ 3,608 Weighted-average basic shares outstanding 1,568 1,595 1,579 1,595 Basic earnings per share $ 1.26 $ 1.20 $ 3.00 $ 2.26 Diluted EPS Net earnings $ 1,983 $ 1,915 $ 4,766 $ 3,626 Earnings allocated to participating securities 10 9 22 18 Earnings available to common shareholders $ 1,973 $ 1,906 $ 4,744 $ 3,608 Weighted-average shares of common stock outstanding 1,568 1,595 1,579 1,595 Effect of dilutive securities 4 5 5 7 Weighted-average diluted shares outstanding 1,572 1,600 1,584 1,602 Diluted earnings per share $ 1.26 $ 1.19 $ 2.99 $ 2.25 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Licensing, Acquisitions, and Ot

Licensing, Acquisitions, and Other Arrangements	6 Months Ended
Licensing, Acquisitions, and Other Arrangements	Jun. 30, 2018
Licensing, Acquisitions, and Other Arrangements
Licensing, Acquisitions, and Other Arrangements	Licensing, Acquisitions and Other Arrangements Cash outflows related to acquisitions and investments totaled $401 million for the six months ended June 30, 2018 and $100 million for the six months ended June 30, 2017 . AbbVie recorded no acquired in-process research and development (IPR&D) charges for the three months ended June 30, 2018 and $69 million for the six months ended June 30, 2018 . Acquired IPR&D charges were $15 million for the three and six months ended June 30, 2017 . Calico Life Sciences LLC In June 2018, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of a collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. Under the terms of the agreement, AbbVie and Calico will each contribute an additional $500 million to the collaboration and the term is extended for an additional 3 years . Calico will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027. Following completion of Phase 2a, AbbVie will have the option to exclusively license collaboration compounds. AbbVie will support Calico in its early research and development efforts and, upon exercise, would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. During the three months ended June 30, 2018, AbbVie recorded $500 million in other expense in the condensed consolidated statement of earnings related to its commitments under the agreement.

Collaboration with Janssen Biot

Collaboration with Janssen Biotech, Inc.	6 Months Ended
Collaboration with Janssen Biotech, Inc.	Jun. 30, 2018
Collaboration with Janssen Biotech, Inc.
Collaboration with Janssen Biotech, Inc.	Collaboration with Janssen Biotech, Inc. In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of IMBRUVICA, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to IMBRUVICA, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States. The collaboration provides Janssen with an exclusive license to commercialize IMBRUVICA outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs. In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of IMBRUVICA are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. Outside the United States, Janssen is responsible for and has exclusive rights to commercialize IMBRUVICA. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share. The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended Six months ended (in millions) 2018 2017 2018 2017 United States - Janssen's share of profits (included in cost of products sold) $ 325 $ 247 $ 601 $ 459 International - AbbVie's share of profits (included in net revenues) 157 98 295 192 Global - AbbVie's share of other costs (included in respective line items) 80 75 151 134 AbbVie’s receivable from Janssen, included in accounts receivable, net, was $167 million at June 30, 2018 and $124 million at December 31, 2017 . AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $310 million at June 30, 2018 and $253 million at December 31, 2017 .

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
Goodwill and Intangible Assets	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2017 $ 15,785 Foreign currency translation adjustments (93 ) Balance as of June 30, 2018 $ 15,692 The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of June 30, 2018 , there were no accumulated goodwill impairment losses. Intangible Assets, Net The following table summarizes intangible assets: June 30, 2018 December 31, 2017 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 15,873 $ (5,169 ) $ 10,704 $ 16,138 $ (4,982 ) $ 11,156 License agreements 7,825 (1,616 ) 6,209 7,822 (1,409 ) 6,413 Total definite-lived intangible assets 23,698 (6,785 ) 16,913 23,960 (6,391 ) 17,569 Indefinite-lived research and development 9,990 — 9,990 9,990 — 9,990 Total intangible assets, net $ 33,688 $ (6,785 ) $ 26,903 $ 33,950 $ (6,391 ) $ 27,559 Amortization expense was $324 million for the three months and $654 million for the six months ended June 30, 2018 and $269 million for the three months and $540 million for the six months ended June 30, 2017 . Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings. Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. Indefinite-lived intangible assets as of June 30, 2018 and December 31, 2017 related to the 2016 acquisitions of Stemcentrx and Boehringer Ingelheim compounds. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist. No impairment charges were recorded for the six months ended June 30, 2018 and 2017 .

Restructuring Plans

Restructuring Plans	6 Months Ended
Restructuring Plans	Jun. 30, 2018
Restructuring and Related Activities [Abstract]
Restructuring Plans	Restructuring Plans AbbVie recorded restructuring charges of $1 million for the three months and $23 million for the six months ended June 30, 2018 and $11 million for the three months and $27 million for the six months ended June 30, 2017 . The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2018 : (in millions) Accrued balance as of December 31, 2017 $ 86 Restructuring charges 23 Payments and other adjustments (21 ) Accrued balance as of June 30, 2018 $ 88

Financial Instruments and Fair

Financial Instruments and Fair Value Measures	6 Months Ended
Financial Instruments and Fair Value Measures	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Financial Instruments and Fair Value Measures	Financial Instruments and Fair Value Measures Risk Management Policy See Note 10 to the company's Annual Report on Form 10-K for the year ended December 31, 2017 for a summary of AbbVie's risk management policy and use of derivative instruments. Financial Instruments Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $2.3 billion at June 30, 2018 and $2.2 billion at December 31, 2017 , are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than eighteen months . Accumulated gains and losses as of June 30, 2018 will be reclassified from AOCI and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement. The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange loss in the consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $11.3 billion at June 30, 2018 and $7.7 billion at December 31, 2017 . The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company designated €3.6 billion aggregate principal amount of senior Euro notes as net investment hedges at June 30, 2018 and December 31, 2017 . Realized and unrealized gains and losses from these hedges are included in AOCI. AbbVie is a party to interest rate hedge contracts designated as fair value hedges with notional amounts totaling $11.8 billion at June 30, 2018 and December 31, 2017 . The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. No amounts are excluded from the assessment of effectiveness for cash flow hedges, net investment hedges or fair value hedges. The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets: Fair value – Fair value – (in millions) Balance sheet caption June 30, December 31, 2017 Balance sheet caption June 30, December 31, 2017 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 100 $ 1 Accounts payable and accrued liabilities $ 8 $ 120 Designated as cash flow hedges Other assets 15 — Other long-term liabilities — — Not designated as hedges Prepaid expenses and other 28 22 Accounts payable and accrued liabilities 32 29 Interest rate swaps designated as fair value hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 7 8 Interest rate swaps designated as fair value hedges Other assets — — Other long-term liabilities 637 393 Total derivatives $ 143 $ 23 $ 684 $ 550 While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets. The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss): Three months ended Six months ended (in millions) 2018 2017 2018 2017 Foreign currency forward exchange contracts $ 169 $ (78 ) $ 121 $ (139 ) Assuming market rates remain constant through contract maturities, the company expects to transfer pre-tax unrealized losses of $16 million into cost of products sold for foreign currency cash flow hedges during the next 12 months. Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized pre-tax gains in other comprehensive income (loss) of $270 million for the three months and $136 million for the six months ended June 30, 2018 and recognized pre-tax losses in other comprehensive income (loss) of $239 million for the three months and $339 million for the six months ended June 30, 2017 . The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 11 for the amount of net gains (losses) reclassified out of AOCI. Three months ended Six months ended (in millions) Statement of earnings caption 2018 2017 2018 2017 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ (46 ) $ 46 $ (90 ) $ 63 Not designated as hedges Net foreign exchange loss 128 (25 ) 69 (71 ) Interest rate swaps designated as fair value hedges Interest expense, net (59 ) 47 (243 ) 32 Debt designated as hedged item in fair value hedges Interest expense, net 59 (47 ) 243 (32 ) Fair Value Measures The fair value hierarchy consists of the following three levels: • Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access; • Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and • Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability. The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2018 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant Assets Cash and equivalents $ 3,547 $ 867 $ 2,680 $ — Time deposits 67 — 67 — Debt securities 1,549 — 1,549 — Equity securities 9 9 — — Foreign currency contracts 143 — 143 — Total assets $ 5,315 $ 876 $ 4,439 $ — Liabilities Interest rate hedges $ 644 $ — $ 644 $ — Foreign currency contracts 40 — 40 — Contingent consideration 4,821 — — 4,821 Total liabilities $ 5,505 $ — $ 684 $ 4,821 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2017 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant Assets Cash and equivalents $ 9,303 $ 849 $ 8,454 $ — Debt securities 2,524 — 2,524 — Equity securities 4 4 — — Foreign currency contracts 23 — 23 — Total assets $ 11,854 $ 853 $ 11,001 $ — Liabilities Interest rate hedges $ 401 $ — $ 401 $ — Foreign currency contracts 149 — 149 — Contingent consideration 4,534 — — 4,534 Total liabilities $ 5,084 $ — $ 550 $ 4,534 The fair values of time deposits approximate their amortized cost due to the short maturities of these instruments. The fair values of available-for-sale debt securities were determined based on prices obtained from commercial pricing services. The derivatives entered into by the company were valued using publicized spot curves for interest rate hedges and publicized forward curves for foreign currency contracts. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products still in development. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. At June 30, 2018 , a 50 basis point increase/decrease in the assumed discount rate would have decreased/increased the value of the contingent consideration liabilities by approximately $180 million . Additionally, at June 30, 2018 , a five percentage point increase/decrease in the assumed probability of success across all potential indications would have increased/decreased the value of the contingent consideration liabilities by approximately $410 million . There have been no transfers of assets or liabilities between the fair value measurement levels. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: Six months ended (in millions) 2018 2017 Beginning balance $ 4,534 $ 4,213 Change in fair value recognized in net earnings 337 146 Milestone payments (50 ) — Ending balance $ 4,821 $ 4,359 The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2018 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant observable Significant Liabilities Short-term borrowings $ 3,511 $ 3,508 $ — $ 3,508 $ — Current portion of long-term debt and lease obligations, excluding fair value hedges 3,026 3,026 998 2,028 — Long-term debt and lease obligations, excluding fair value hedges 31,216 30,750 30,675 75 — Total liabilities $ 37,753 $ 37,284 $ 31,673 $ 5,611 $ — AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $76 million as of June 30, 2018 . No significant cumulative upward or downward adjustments have been recorded for these investments as of June 30, 2018 . Prior to the adoption of ASU No. 2016-01 discussed in Note 1, these investments were accounted for under the cost method and disclosed in the table below as of December 31, 2017 . The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2017 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant observable Significant Assets Investments $ 48 $ 48 $ — $ — $ 48 Total assets $ 48 $ 48 $ — $ — $ 48 Liabilities Short-term borrowings $ 400 $ 400 $ — $ 400 $ — Current portion of long-term debt and lease obligations, excluding fair value hedges 6,023 6,034 4,004 2,030 — Long-term debt and lease obligations, excluding fair value hedges 31,346 32,846 32,763 83 — Total liabilities $ 37,769 $ 39,280 $ 36,767 $ 2,513 $ — Available-for-sale Securities Substantially all of the company’s investments in debt securities were classified as available-for-sale with changes in fair value recognized in other comprehensive income. Debt securities classified as short-term were $128 million as of June 30, 2018 and $482 million as of December 31, 2017 . Long-term debt securities mature primarily within five years . Estimated fair values of available-for-sale debt securities were generally determined based on prices obtained from commercial pricing services. The following table is a summary of available-for-sale securities by type as of June 30, 2018 : Amortized cost Gross unrealized Fair value (in millions) Gains Losses Asset backed securities $ 455 $ 1 $ (2 ) $ 454 Corporate debt securities 1,018 3 (3 ) 1,018 Other debt securities 78 — (1 ) 77 Total $ 1,551 $ 4 $ (6 ) $ 1,549 The following table is a summary of available-for-sale securities by type as of December 31, 2017 : Amortized cost Gross unrealized Fair value (in millions) Gains Losses Asset backed securities $ 930 $ 1 $ (3 ) $ 928 Corporate debt securities 1,451 4 (2 ) 1,453 Other debt securities 144 — (1 ) 143 Equity securities 4 2 (2 ) 4 Total $ 2,529 $ 7 $ (8 ) $ 2,528 AbbVie had no other-than-temporary impairments as of June 30, 2018 . Net realized gains (losses) were insignificant for both the three and six months ended June 30, 2018 and 2017 . Concentrations of Risk AbbVie continues to do business with foreign governments in certain countries, including Greece, Portugal, Italy and Spain, which have historically experienced challenges in credit and economic conditions. Substantially all of AbbVie’s trade receivables in Greece, Portugal, Italy and Spain are with government health systems. Outstanding governmental receivables in these countries, net of allowances for doubtful accounts, totaled $286 million as of June 30, 2018 and $255 million as of December 31, 2017 . The company also continues to do business with foreign governments in certain oil-exporting countries that have experienced a deterioration in economic conditions, including Saudi Arabia and Russia, which may result in delays in the collection of receivables. Outstanding governmental receivables related to Saudi Arabia, net of allowances for doubtful accounts, were $162 million as of June 30, 2018 and $149 million as of December 31, 2017 . Outstanding governmental receivables related to Russia, net of allowances for doubtful accounts, were $75 million as of June 30, 2018 and $152 million as of December 31, 2017 . Global economic conditions and customer-specific factors may require the company to periodically re-evaluate the collectability of its receivables and the company could potentially incur credit losses. Of total net accounts receivable, three U.S. wholesalers accounted for 59% as of June 30, 2018 and 56% as of December 31, 2017 , and substantially all of AbbVie’s net revenues in the United States were to these three wholesalers. HUMIRA (adalimumab) is AbbVie’s single largest product and accounted for approximately 61% of AbbVie’s total net revenues for the six months ended June 30, 2018 and 66% for the six months ended June 30, 2017 . Debt and Credit Facilities Short-term borrowings included commercial paper borrowings of $511 million as of June 30, 2018 and $400 million as of December 31, 2017 . The weighted-average interest rate on commercial paper borrowings was 1.9% for the six months ended June 30, 2018 and 1.1% for the six months ended June 30, 2017 . On May 17, 2018, AbbVie entered into a $3.0 billion 364 -day term loan credit agreement (term loan). In June 2018, the company drew on this term loan and as of June 30, 2018, $3.0 billion was outstanding and was included in short-term borrowings on the condensed consolidated balance sheet. Borrowings under the term loan bear interest at one month LIBOR plus applicable margin. The term loan may be prepaid without penalty upon prior notice and contains customary covenants, all of which the company was in compliance with as of June 30, 2018. In May 2018, the company also repaid $3.0 billion aggregate principal amount of its 1.80% senior notes at maturity.

Post-Employment Benefits

Post-Employment Benefits	6 Months Ended
Post-Employment Benefits	Jun. 30, 2018
Postemployment Benefits [Abstract]
Post-Employment Benefits	Post-Employment Benefits The following is a summary of net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Six months ended Three months ended Six months ended (in millions) 2018 2017 2018 2017 2018 2017 2018 2017 Service cost $ 72 $ 59 $ 144 $ 117 $ 5 $ 6 $ 13 $ 13 Interest cost 57 51 114 101 4 6 12 12 Expected return on plan assets (110 ) (95 ) (221 ) (190 ) — — — — Amortization of actuarial losses and prior service costs 39 27 76 53 (3 ) (1 ) 1 — Net periodic benefit cost $ 58 $ 42 $ 113 $ 81 $ 6 $ 11 $ 26 $ 25 The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.

Equity

Equity	6 Months Ended
Equity	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
Equity	Equity Stock-Based Compensation Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows: Three months ended Six months ended (in millions) 2018 2017 2018 2017 Cost of products sold $ 12 $ 10 $ 16 $ 13 Research and development 35 33 107 97 Selling, general and administrative 38 33 153 107 Pre-tax compensation expense 85 76 276 217 Tax benefit 19 18 48 65 After-tax compensation expense $ 66 $ 58 $ 228 $ 152 Stock Options During the six months ended June 30, 2018 , primarily in connection with the company's annual grant, AbbVie granted 0.6 million stock options with a weighted-average grant-date fair value of $21.63 . As of June 30, 2018 , $11 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years . RSAs, RSUs and Performance Shares During the six months ended June 30, 2018 , primarily in connection with the company's annual grant, AbbVie granted 3.8 million RSUs and performance shares with a weighted-average grant-date fair value of $114.69 . As of June 30, 2018 , $400 million of unrecognized compensation cost related to RSAs, RSUs and performance shares is expected to be recognized as expense over approximately the next two years . Cash Dividends The following table summarizes quarterly cash dividends declared during 2018 and 2017 : 2018 2017 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 06/14/18 08/15/18 $ 0.96 10/27/17 02/15/18 $ 0.71 02/15/18 05/15/18 $ 0.96 09/08/17 11/15/17 $ 0.64 06/22/17 08/15/17 $ 0.64 02/16/17 05/15/17 $ 0.64 Stock Repurchase Program On February 15, 2018, AbbVie's board of directors authorized a new $10.0 billion stock repurchase program, which superseded AbbVie's previous stock repurchase program. The new stock repurchase program permits purchases of AbbVie shares from time to time in open-market or private transactions, including accelerated share repurchases, at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes. As part of this repurchase program, on June 4, 2018, AbbVie completed a modified "Dutch auction" tender offer and paid an aggregate of $7.5 billion , excluding fees and related expenses, to repurchase 72.8 million shares at tender price of $103.00 per share. In addition to the shares repurchased under the tender offer, AbbVie repurchased approximately 10.9 million shares in the open market for $1.3 billion during the six months ended June 30, 2018 . These repurchases were made prior to the new $10.0 billion authorization. AbbVie's remaining stock repurchase authorization was $2.5 billion as of June 30, 2018 . Accumulated Other Comprehensive Loss The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2018 : (in millions) Foreign Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2017 $ (439 ) $ (203 ) $ (1,919 ) $ — $ (166 ) $ (2,727 ) Other comprehensive income (loss) before reclassifications (280 ) 105 9 (6 ) 110 (62 ) Net losses reclassified from accumulated other comprehensive loss — — 62 4 84 150 Net current-period other comprehensive income (loss) (280 ) 105 71 (2 ) 194 88 Balance as of June 30, 2018 $ (719 ) $ (98 ) $ (1,848 ) $ (2 ) $ 28 $ (2,639 ) Other comprehensive income for the six months ended June 30, 2018 included foreign currency translation adjustments totaling a loss of $280 million , which was principally due to the weakening of the Euro in the six months ended June 30, 2018 on the translation of the company’s assets denominated in the Euro. The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2017 : (in millions) Foreign Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2016 $ (1,435 ) $ 140 $ (1,513 ) $ 46 $ 176 $ (2,586 ) Other comprehensive income (loss) before reclassifications 419 (217 ) (25 ) 20 (129 ) 68 Net losses (gains) reclassified from accumulated other comprehensive loss — — 38 (10 ) (58 ) (30 ) Net current-period other comprehensive income (loss) 419 (217 ) 13 10 (187 ) 38 Balance as of June 30, 2017 $ (1,016 ) $ (77 ) $ (1,500 ) $ 56 $ (11 ) $ (2,548 ) Other comprehensive income for the six months ended June 30, 2017 included foreign currency translation adjustments totaling a gain of $419 million , which was principally due to the impact of the improvement in the Euro in the six months ended June 30, 2017 on the translation of the company’s assets denominated in the Euro. The table below presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: Three months ended Six months ended (in millions) (brackets denote gains) 2018 2017 2018 2017 Pension and post-employment benefits Amortization of actuarial losses and other (a) $ 36 $ 26 $ 77 $ 53 Tax benefit (7 ) (7 ) (15 ) (15 ) Total reclassifications, net of tax $ 29 $ 19 $ 62 $ 38 Cash flow hedging activities Losses (gains) on designated cash flow hedges (b) $ 46 $ (46 ) $ 90 $ (63 ) Tax expense (benefit) (4 ) 4 (6 ) 5 Total reclassifications, net of tax $ 42 $ (42 ) $ 84 $ (58 ) (a) Amounts are included in the computation of net periodic benefit cost (see Note 10 ). (b) Amounts are included in cost of products sold (see Note 9 ).

Income Taxes

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rate was 2% for the three months and 1% for the six months ended June 30, 2018 and 19% for the three months and 18% for the six months ended June 30, 2017 . The effective tax rate in each period differed from the U.S. statutory tax rates of 21% in 2018 and 35% in 2017, principally due to the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax exemptions and incentives in Puerto Rico and other foreign tax jurisdictions and business development activities. The change in the effective tax rate for the three and six months ended June 30, 2018 over the prior year was principally due to the effects of the enactment of the Tax Cuts and Jobs Act (the “Act”) in December 2017. The Act significantly changes the U.S. corporate tax system, reducing the U.S. federal corporate tax rate from 35% to 21% , requiring companies to pay a one-time transition tax on a mandatory deemed repatriation of earnings of certain foreign subsidiaries that were previously untaxed and creating new taxes on certain foreign sourced earnings. The Act also creates a territorial tax system that generally excludes dividends from foreign subsidiaries from U.S. taxation. Specific to 2018, there is a beneficial impact due to timing of provisions related to the earnings from certain foreign subsidiaries. Given the complexity of the Act and anticipated guidance from the U.S. Treasury about implementing the Act, the company’s analysis and accounting for the tax effects of the enactment of the Act is preliminary. In the fourth quarter of 2017, the company recorded, as a direct result of the Act, $4.5 billion of transition tax expense, as well as $4.1 billion of net tax benefit for deferred tax remeasurement. Both of these amounts are provisional estimates, as the company has not fully completed its analysis and calculation of foreign earnings subject to the transition tax or its analysis of certain other aspects of the Act that could result in adjustments to the remeasurement of deferred tax balances. Upon completion of the analysis in 2018, these estimates may be adjusted through income tax expense in the consolidated statement of earnings. No adjustments to these provisional estimates were made during the three and six months ended June 30, 2018 . The Act also created a minimum tax on certain foreign sourced earnings. The taxability of the foreign sourced earnings and the applicable tax rates are dependent on future events. While the company is still evaluating its accounting policy for the minimum tax on foreign sourced earnings, the provisional estimates of the tax effects of the Act were reported on the basis that the minimum tax will be recognized in tax expense in the year it is incurred as a period expense. Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company’s gross unrecognized tax benefits balance may change within the next twelve months by up to $272 million . At the time of separation, AbbVie and Abbott Laboratories (Abbott) entered into a tax sharing agreement which provides that Abbott is liable for and has indemnified AbbVie against all income tax liabilities for periods prior to the separation. Accordingly, Abbott will indemnify and hold AbbVie harmless if the tax positions are settled for amounts in excess of recorded liabilities, and AbbVie will not benefit if prior tax positions are resolved more favorably than recorded amounts.

Legal Proceedings and Contingen

Legal Proceedings and Contingencies	6 Months Ended
Legal Proceedings and Contingencies	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies	Legal Proceedings and Contingencies AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. The recorded accrual balance for litigation was approximately $560 million as of June 30, 2018 and $445 million as of December 31, 2017 . Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows. Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. Several pending lawsuits filed against Unimed Pharmaceuticals, Inc., Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) and others are consolidated for pre-trial purposes in the United States District Court for the Northern District of Georgia under the Multi-District Litigation (MDL) Rules as In re: AndroGel Antitrust Litigation , MDL No. 2084. These cases, brought by private plaintiffs and the Federal Trade Commission (FTC), generally allege Solvay's patent litigation involving AndroGel was sham litigation and the 2006 patent litigation settlement agreements and related agreements with three generic companies violate federal antitrust laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. These cases include: (a) four individual plaintiff lawsuits; (b) three purported class actions; and (c) Federal Trade Commission v. Actavis, Inc. et al. Following the district court's dismissal of all plaintiffs' claims, appellate proceedings led to the reinstatement of the claims regarding the patent litigation settlements, which are proceeding in the district court. In July 2018, the court denied the purported class members’ motion for class certification. Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by three named direct purchasers of Niaspan and the other brought by ten named end-payer purchasers of Niaspan. The cases are consolidated for pre-trial proceedings in the United States District Court for the Eastern District of Pennsylvania under the MDL Rules as In re: Niaspan Antitrust Litigation , MDL No. 2460. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In May 2018, the California Court of Appeals ruled that the District Attorney’s Office may not bring monetary claims beyond the scope of Orange County. A suit is pending in the United States District Court for the Eastern District of Pennsylvania filed in September 2014 by the FTC against AbbVie and others, alleging that the 2011 patent litigation with two generic companies regarding AndroGel was sham litigation. The FTC's complaint seeks monetary damages and injunctive relief. In June 2018, following a bench trial, the court found for the FTC on its sham litigation claim and ordered a disgorgement remedy of $448 million , plus prejudgment interest. The court denied the FTC’s request for injunctive relief. AbbVie intends to appeal the court’s liability and disgorgement rulings and, based on an assessment of the merits of that appeal, no liability has been accrued for this matter. In March 2015, the State of Louisiana filed a lawsuit, State of Louisiana v. Fournier Industrie et Sante, et al. , against AbbVie, Abbott and affiliated Abbott entities in Louisiana state court. Plaintiff alleges that patent applications and patent litigation filed and other alleged conduct from the early 2000's and before related to the drug TriCor violated Louisiana State antitrust and unfair trade practices laws. The lawsuit seeks monetary damages and attorneys' fees. In November 2014, a putative class action lawsuit, Medical Mutual of Ohio v. AbbVie Inc., et al. , was filed against several manufacturers of testosterone replacement therapies (TRTs), including AbbVie, in the United States District Court for the Northern District of Illinois on behalf of all insurance companies, health benefit providers, and other third party payers who paid for TRTs, including AndroGel. The claims asserted include violations of the federal RICO Act and state consumer fraud and deceptive trade practices laws. The complaint seeks monetary damages and injunctive relief. Product liability cases are pending in which plaintiffs generally allege that AbbVie and other manufacturers of TRTs did not adequately warn about risks of certain injuries, primarily heart attacks, strokes and blood clots. Approximately 4,130 claims are consolidated for pre-trial purposes in the United States District Court for the Northern District of Illinois under the MDL Rules as In re: Testosterone Replacement Therapy Products Liability Litigation , MDL No. 2545. Approximately 200 claims against AbbVie are pending in various state courts. Plaintiffs generally seek compensatory and punitive damages. Six cases have gone to trial. Four of those have resulted in complete verdicts for AbbVie: three by juries in the United States District Court for the Northern District of Illinois in January, May, and June 2018, and one by a jury in the Cook County, Illinois Circuit Court in August 2017. Another case in the United States District Court for the Northern District of Illinois resulted in a jury verdict for AbbVie on two claims and for the plaintiff on one claim and an award of $150 million in punitive damages with no compensatory damages in July 2017. In orders from December 2017 and February 2018, the court vacated that verdict and ordered a new trial. In the March 2018 retrial, the jury reached a verdict for AbbVie on strict liability and fraud and for the plaintiff on negligence and awarded $200,000 in compensatory damages and $3 million in punitive damages, which is the subject of post-trial proceedings. Another case in the United States District Court for the Northern District of Illinois resulted in a jury verdict for AbbVie on strict liability and for the plaintiff on remaining claims and an award of $140,000 in compensatory damages and $140 million in punitive damages in August 2017. In July 2018, the court vacated that verdict and ordered a new trial. Product liability cases are pending in which plaintiffs generally allege that AbbVie did not adequately warn about risk of certain injuries, primarily various birth defects, arising from use of Depakote. Over ninety percent of the approximately 596 claims are pending in the United States District Court for the Southern District of Illinois, and the rest are pending in various other federal and state courts. Plaintiffs generally seek compensatory and punitive damages. In November 2014, five individuals filed a putative class action lawsuit, Rubinstein, et al. v Gonzalez, et al., on behalf of purchasers and sellers of certain Shire plc (Shire) securities between June 20 and October 14, 2014, against AbbVie and its chief executive officer in the United States District Court for the Northern District of Illinois alleging that the defendants made and/or are responsible for material misstatements in violation of federal securities laws in connection with AbbVie's proposed transaction with Shire. In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc. , was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connec tion with its proposed t ransaction with Shire. Similar lawsuits were filed between July 2017 and May 2018 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. Plaintiffs seek compensatory and punitive damages. In May 2017, a shareholder derivative lawsuit, Ellis v. Gonzalez, et al. , was filed in Delaware Chancery Court, alleging that AbbVie's directors breached their fiduciary duties in connection with statements made regarding the Shire transaction. The lawsuit sought unspecified compensatory damages for AbbVie, among other relief. In July 2018, the court dismissed this case with prejudice. Beginning in May 2016, the Patent Trial & Appeal Board of the U.S. Patent & Trademark Office (PTO) instituted five inter partes review proceedings brought by Coherus Biosciences and Boehringer Ingelheim related to three AbbVie patents covering methods of treatment of rheumatoid arthritis using adalimumab. In these proceedings, the PTO reviewed the validity of the patents and issued decisions of invalidity in May, June and July of 2017. AbbVie’s appeal of the decisions is pending in the Court of Appeals for the Federal Circuit. In March 2017, AbbVie filed a lawsuit, AbbVie Inc. v. Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd., in the United States District Court for the Northern District of California against Novartis Vaccines and Grifols Worldwide seeking a declaratory judgment that eleven HCV-related patents licensed to AbbVie in 2002 are invalid. AbbVie is seeking to enforce certain patent rights related to adalimumab (a drug AbbVie sells under the trademark HUMIRA®). In a case filed in United States District Court for the District of Delaware in August 2017, AbbVie alleges that Boehringer Ingelheim International GmbH’s, Boehringer Ingelheim Pharmaceutical, Inc.’s, and Boehringer Ingelheim Fremont, Inc.’s proposed biosimilar adalimumab product infringes certain AbbVie patents. AbbVie seeks declaratory and injunctive relief. Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib capsules (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In February 2018, four separate cases were filed in the United States District Court for the District of Delaware against the following defendants: Fresenius Kabi USA, LLC, Fresenius Kabi USA, Inc., and Fresenius Kabi Oncology Limited; Shilpa Medicare Limited, Sun Pharma Global FZE and Sun Pharmaceutical Industries Ltd.; Cipla Limited and Cipla USA Inc.; and Zydus Worldwide DMCC, Cadila Healthcare Limited, Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., and Lek Pharmaceuticals D.D. In each case, Pharmacyclics alleges the defendant’s proposed generic ibrutinib product infringes certain Pharmacyclics patents and seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in these suits. In April 2018, a lawsuit, Acerta Pharma B.V., AstraZeneca UK Ltd., and AstraZeneca Pharmaceuticals LP v. Pharmacyclics LLC and AbbVie Inc. , was filed in the Federal District Court of Delaware alleging that IMBRUVICA infringes an Acerta patent. The plaintiffs seek damages.

Segment Information

Segment Information	6 Months Ended
Segment Information	Jun. 30, 2018
Segment Reporting [Abstract]
Segment Information	Segment Information AbbVie operates in one business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues: Three months ended Six months ended (in millions) 2018 2017 2018 2017 HUMIRA United States $ 3,521 $ 3,201 $ 6,524 $ 5,897 International 1,664 1,515 3,370 2,937 Total $ 5,185 $ 4,716 $ 9,894 $ 8,834 IMBRUVICA United States $ 693 $ 528 $ 1,317 $ 985 Collaboration revenues 157 98 295 192 Total $ 850 $ 626 $ 1,612 $ 1,177 HCV United States $ 422 $ 26 $ 765 $ 64 International 551 199 1,127 424 Total $ 973 $ 225 $ 1,892 $ 488 Creon United States $ 219 $ 196 $ 428 $ 381 Lupron United States $ 180 $ 172 $ 357 $ 327 International 43 38 85 77 Total $ 223 $ 210 $ 442 $ 404 Synthroid United States $ 193 $ 193 $ 375 $ 385 Synagis International $ 44 $ 40 $ 365 $ 340 AndroGel United States $ 128 $ 154 $ 258 $ 290 Duodopa United States $ 20 $ 14 $ 38 $ 28 International 88 67 173 133 Total $ 108 $ 81 $ 211 $ 161 Sevoflurane United States $ 19 $ 19 $ 36 $ 37 International 94 85 183 174 Total $ 113 $ 104 $ 219 $ 211 Kaletra United States $ 13 $ 19 $ 26 $ 38 International 78 91 138 187 Total $ 91 $ 110 $ 164 $ 225 All other $ 151 $ 289 $ 352 $ 586 Total net revenues $ 8,278 $ 6,944 $ 16,212 $ 13,482

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
Basis of Presentation (Policies)	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements ASU No. 2014-09 In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Summary and Amendments That Create Revenue from Contracts with Customers (Topic 606) and Other Assets and Deferred Costs - Contracts with Customers (Subtopic 340-40) . The amendments in this standard superseded most existing revenue recognition requirements. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. AbbVie adopted the standard in the first quarter of 2018 using the modified retrospective method. Results for reporting periods beginning after December 31, 2017 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie’s historical accounting. The cumulative effect of initially applying the new revenue standard was recognized as an adjustment to the opening balance of retained earnings as of January 1, 2018. There were no significant changes to the amounts or timing of revenue recognition for product sales, the company's primary revenue stream. For certain licensing arrangements where revenue was previously deferred and recognized over time, revenue is now recognized at the point in time when the license is granted. Additionally, for certain contract manufacturing arrangements where revenue was previously recognized at a point in time at the end of the manufacturing process, revenue is now recognized over time throughout the manufacturing process. Under the new standard, on January 1, 2018, the company recognized a cumulative-effect adjustment to retained earnings primarily related to certain deferred license revenues that were originally expected to be recognized through early 2020. The adjustment to the condensed consolidated balance sheet included: (i) a $42 million increase to prepaid expenses and other; (ii) a $39 million decrease to inventories; (iii) a $57 million decrease to accounts payable and accrued liabilities; (iv) a $75 million decrease to other long-term liabilities; (v) a $22 million increase to deferred income taxes; and (vi) a $124 million increase to retained earnings. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant. The impact of adoption on the company’s condensed consolidated statement of earnings for the three and six months ended June 30, 2018 was as follows: Three months ended Six months ended (in millions, except per share data) As Reported Balances Without Adoption of ASU 2014-09 Effect of Change Higher/(Lower) As Reported Balances Without Adoption of ASU 2014-09 Effect of Change Higher/(Lower) Net revenues $ 8,278 $ 8,291 $ (13 ) $ 16,212 $ 16,182 $ 30 Cost of products sold 1,934 1,939 (5 ) 3,861 3,845 16 Income tax expense 29 29 — 43 36 7 Net earnings 1,983 1,991 (8 ) 4,766 4,759 7 Diluted earnings per share $ 1.26 $ 1.26 $ — $ 2.99 $ 2.99 $ — As of June 30, 2018 , due to the impact of the adoption of ASU 2014-09, prepaid expenses and other were $101 million higher, inventories were $54 million lower, accounts payable and accrued liabilities were $46 million lower, other long-term liabilities were $46 million lower, deferred income taxes were $16 million higher and retained earnings were $131 million higher on the company’s condensed consolidated balance sheet than they would have been had ASU 2014-09 not been adopted. Other impacts to the condensed consolidated balance sheet were insignificant. ASU No. 2016-01 In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities . The standard requires several targeted changes including that equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) be measured at fair value with changes in fair value recognized in net earnings. AbbVie adopted the standard in the first quarter of 2018. The adoption did not impact the accounting for AbbVie's investments in debt securities and did not have a material impact on the company's consolidated financial statements. ASU No. 2016-16 In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740) . The standard requires entities to recognize the income tax consequences of an intercompany transfer of an asset other than inventory when the transfer occurs. Under previous U.S. GAAP, the income tax consequences of these intercompany asset transfers were deferred until the asset was sold to a third party or otherwise recovered through use. AbbVie adopted the standard in the first quarter of 2018 using the modified retrospective method. As a result, on January 1, 2018, the company recorded a cumulative-effect adjustment to its condensed consolidated balance sheet that included a $1.9 billion decrease to retained earnings, a $1.4 billion decrease to prepaid expenses and other and a $0.5 billion decrease to other assets. ASU No. 2017-07 In March 2017, the FASB issued ASU No. 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost . The standard requires that an employer continue to report the service cost component of net periodic benefit cost in the same income statement line item or items as other employee compensation costs arising from services rendered during the period. The other components of net periodic benefit cost are required to be presented separately outside of income from operations and are not eligible for capitalization. AbbVie adopted the standard in the first quarter of 2018 and applied the income statement classification provisions of this standard retrospectively. As a result, the company reclassified income of $12 million from operating earnings to non-operating income for the three months and $24 million for the six months ended June 30, 2017 . Additionally, the company recorded approximately $14 million of non-operating income for the three months and $18 million for the six months ended June 30, 2018 which would have been recorded in operating earnings under the previous guidance. ASU No. 2017-12 In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The standard simplifies the application of hedge accounting and more closely aligns the accounting with an entity’s risk management activities. AbbVie elected to early adopt the standard in the first quarter of 2018. The adoption did not have a material impact on the company's consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted ASU No. 2016-02 In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) . The standard outlines a comprehensive lease accounting model that supersedes the current lease guidance and requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new standard must be adopted using the modified retrospective approach and will be effective for AbbVie starting with the first quarter of 2019, with early adoption permitted. AbbVie will adopt the standard effective in the first quarter of 2019 and is currently assessing the impact of adopting this guidance on its consolidated financial statements and related disclosures. AbbVie does not expect the adoption will have a material impact on its consolidated statement of earnings. However, the new standard will require AbbVie to establish liabilities and corresponding right-of-use assets on its consolidated balance sheet for operating leases that exist as of the January 1, 2019 adoption date. ASU No. 2016-13 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) . The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. Early adoption beginning in the first quarter of 2019 is permitted. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact and timing of adopting this guidance on its consolidated financial statements. ASU No. 2018-02 In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allows a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act. The standard will be effective for AbbVie starting with the first quarter of 2019, with early adoption permitted. AbbVie is currently assessing the impact and timing of adopting this guidance on its consolidated financial statements.

Revenue Recognition (Policies)

Revenue Recognition (Policies)	6 Months Ended
Revenue Recognition (Policies)	Jun. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition	AbbVie recognizes revenue when control of promised goods or services is transferred to the company’s customers, in an amount that reflects the consideration AbbVie expects to be entitled to in exchange for those goods or services. Sales, value add and other taxes collected concurrent with revenue-producing activities are excluded from revenue. AbbVie generates revenue primarily from product sales. For the majority of sales, the company transfers control, invoices the customer and recognizes revenue upon shipment to the customer. The company recognizes shipping and handling costs as an expense in cost of products sold when the company transfers control to the customer. Payment terms vary depending on the type and location of the customer, are based on customary commercial terms and are generally less than one year. AbbVie does not adjust revenue for the effects of a significant financing component for contracts where AbbVie expects the period between the transfer of the good or service and collection to be one year or less. Discounts, rebates, sales incentives to customers, returns and certain other adjustments are accounted for as variable consideration. Provisions for variable consideration are based on current pricing, executed contracts, government pricing legislation and historical data and are provided for in the period the related revenues are recorded. Rebate amounts are typically based upon the volume of purchases using contractual or statutory prices, which may vary by product and by payer. For each type of rebate, factors used in the calculation of the accrual include the identification of the products subject to the rebate, the applicable price terms and the estimated lag time between sale and payment of the rebate, which can be significant. Sales incentives to customers are insignificant.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	6 Months Ended
Basis of Presentation (Tables)	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of impact of adoption on condensed consolidated statement of earnings	The impact of adoption on the company’s condensed consolidated statement of earnings for the three and six months ended June 30, 2018 was as follows: Three months ended Six months ended (in millions, except per share data) As Reported Balances Without Adoption of ASU 2014-09 Effect of Change Higher/(Lower) As Reported Balances Without Adoption of ASU 2014-09 Effect of Change Higher/(Lower) Net revenues $ 8,278 $ 8,291 $ (13 ) $ 16,212 $ 16,182 $ 30 Cost of products sold 1,934 1,939 (5 ) 3,861 3,845 16 Income tax expense 29 29 — 43 36 7 Net earnings 1,983 1,991 (8 ) 4,766 4,759 7 Diluted earnings per share $ 1.26 $ 1.26 $ — $ 2.99 $ 2.99 $ —

Supplemental Financial Inform25

Supplemental Financial Information (Tables)	6 Months Ended
Supplemental Financial Information (Tables)	Jun. 30, 2018
Supplemental Financial Information
Schedule of interest expense, net	Interest Expense, Net Three months ended Six months ended (in millions) 2018 2017 2018 2017 Interest expense $ 320 $ 284 $ 629 $ 557 Interest income (48 ) (31 ) (106 ) (57 ) Interest expense, net $ 272 $ 253 $ 523 $ 500
Schedule of inventories	Inventories (in millions) June 30, 2018 December 31, 2017 Finished goods $ 465 $ 610 Work-in-process 924 822 Raw materials 191 173 Inventories $ 1,580 $ 1,605
Schedule of property and equipment	Property and Equipment (in millions) June 30, 2018 December 31, 2017 Property and equipment, gross $ 8,214 $ 8,071 Accumulated depreciation (5,427 ) (5,268 ) Property and equipment, net $ 2,787 $ 2,803

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
Earnings Per Share (Tables)	Jun. 30, 2018
Earnings Per Share [Abstract]
Summary of diluted earnings per share, impact of two-class method	The following table summarizes the impact of the two-class method: Three months ended Six months ended (in millions, except per share data) 2018 2017 2018 2017 Basic EPS Net earnings $ 1,983 $ 1,915 $ 4,766 $ 3,626 Earnings allocated to participating securities 10 9 22 18 Earnings available to common shareholders $ 1,973 $ 1,906 $ 4,744 $ 3,608 Weighted-average basic shares outstanding 1,568 1,595 1,579 1,595 Basic earnings per share $ 1.26 $ 1.20 $ 3.00 $ 2.26 Diluted EPS Net earnings $ 1,983 $ 1,915 $ 4,766 $ 3,626 Earnings allocated to participating securities 10 9 22 18 Earnings available to common shareholders $ 1,973 $ 1,906 $ 4,744 $ 3,608 Weighted-average shares of common stock outstanding 1,568 1,595 1,579 1,595 Effect of dilutive securities 4 5 5 7 Weighted-average diluted shares outstanding 1,572 1,600 1,584 1,602 Diluted earnings per share $ 1.26 $ 1.19 $ 2.99 $ 2.25

Collaboration with Janssen Bi27

Collaboration with Janssen Biotech, Inc. (Tables)	6 Months Ended
Collaboration with Janssen Biotech, Inc. (Tables)	Jun. 30, 2018
Collaboration with Janssen Biotech, Inc.
Schedule of profit and cost sharing relationship	The following table shows the profit and cost sharing relationship between Janssen and AbbVie: Three months ended Six months ended (in millions) 2018 2017 2018 2017 United States - Janssen's share of profits (included in cost of products sold) $ 325 $ 247 $ 601 $ 459 International - AbbVie's share of profits (included in net revenues) 157 98 295 192 Global - AbbVie's share of other costs (included in respective line items) 80 75 151 134

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
Goodwill and Intangible Assets (Tables)	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of changes in the carrying amount of goodwill	The following table summarizes the changes in the carrying amount of goodwill: (in millions) Balance as of December 31, 2017 $ 15,785 Foreign currency translation adjustments (93 ) Balance as of June 30, 2018 $ 15,692
Summary of definite-lived intangible assets	The following table summarizes intangible assets: June 30, 2018 December 31, 2017 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 15,873 $ (5,169 ) $ 10,704 $ 16,138 $ (4,982 ) $ 11,156 License agreements 7,825 (1,616 ) 6,209 7,822 (1,409 ) 6,413 Total definite-lived intangible assets 23,698 (6,785 ) 16,913 23,960 (6,391 ) 17,569 Indefinite-lived research and development 9,990 — 9,990 9,990 — 9,990 Total intangible assets, net $ 33,688 $ (6,785 ) $ 26,903 $ 33,950 $ (6,391 ) $ 27,559
Summary of indefinite-lived intangible assets	The following table summarizes intangible assets: June 30, 2018 December 31, 2017 (in millions) Gross Accumulated Net Gross Accumulated Net Definite-lived intangible assets Developed product rights $ 15,873 $ (5,169 ) $ 10,704 $ 16,138 $ (4,982 ) $ 11,156 License agreements 7,825 (1,616 ) 6,209 7,822 (1,409 ) 6,413 Total definite-lived intangible assets 23,698 (6,785 ) 16,913 23,960 (6,391 ) 17,569 Indefinite-lived research and development 9,990 — 9,990 9,990 — 9,990 Total intangible assets, net $ 33,688 $ (6,785 ) $ 26,903 $ 33,950 $ (6,391 ) $ 27,559

Restructuring Plans (Tables)

Restructuring Plans (Tables)	6 Months Ended
Restructuring Plans (Tables)	Jun. 30, 2018
Restructuring and Related Activities [Abstract]
Summary of the cash activity in the restructuring reserve	The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2018 : (in millions) Accrued balance as of December 31, 2017 $ 86 Restructuring charges 23 Payments and other adjustments (21 ) Accrued balance as of June 30, 2018 $ 88

Financial Instruments and Fai30

Financial Instruments and Fair Value Measures (Tables)	6 Months Ended
Financial Instruments and Fair Value Measures (Tables)	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Summary of amounts and location of derivatives on the condensed consolidated balance sheets	The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets: Fair value – Fair value – (in millions) Balance sheet caption June 30, December 31, 2017 Balance sheet caption June 30, December 31, 2017 Foreign currency forward exchange contracts Designated as cash flow hedges Prepaid expenses and other $ 100 $ 1 Accounts payable and accrued liabilities $ 8 $ 120 Designated as cash flow hedges Other assets 15 — Other long-term liabilities — — Not designated as hedges Prepaid expenses and other 28 22 Accounts payable and accrued liabilities 32 29 Interest rate swaps designated as fair value hedges Prepaid expenses and other — — Accounts payable and accrued liabilities 7 8 Interest rate swaps designated as fair value hedges Other assets — — Other long-term liabilities 637 393 Total derivatives $ 143 $ 23 $ 684 $ 550
Schedule of pre-tax amounts of derivatives recognized in other comprehensive income (loss)	The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss): Three months ended Six months ended (in millions) 2018 2017 2018 2017 Foreign currency forward exchange contracts $ 169 $ (78 ) $ 121 $ (139 )
Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings	The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 11 for the amount of net gains (losses) reclassified out of AOCI. Three months ended Six months ended (in millions) Statement of earnings caption 2018 2017 2018 2017 Foreign currency forward exchange contracts Designated as cash flow hedges Cost of products sold $ (46 ) $ 46 $ (90 ) $ 63 Not designated as hedges Net foreign exchange loss 128 (25 ) 69 (71 ) Interest rate swaps designated as fair value hedges Interest expense, net (59 ) 47 (243 ) 32 Debt designated as hedged item in fair value hedges Interest expense, net 59 (47 ) 243 (32 )
Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis	The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2018 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant Assets Cash and equivalents $ 3,547 $ 867 $ 2,680 $ — Time deposits 67 — 67 — Debt securities 1,549 — 1,549 — Equity securities 9 9 — — Foreign currency contracts 143 — 143 — Total assets $ 5,315 $ 876 $ 4,439 $ — Liabilities Interest rate hedges $ 644 $ — $ 644 $ — Foreign currency contracts 40 — 40 — Contingent consideration 4,821 — — 4,821 Total liabilities $ 5,505 $ — $ 684 $ 4,821 The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2017 : Basis of fair value measurement (in millions) Total Quoted prices in active markets for identical assets Significant other observable Significant Assets Cash and equivalents $ 9,303 $ 849 $ 8,454 $ — Debt securities 2,524 — 2,524 — Equity securities 4 4 — — Foreign currency contracts 23 — 23 — Total assets $ 11,854 $ 853 $ 11,001 $ — Liabilities Interest rate hedges $ 401 $ — $ 401 $ — Foreign currency contracts 149 — 149 — Contingent consideration 4,534 — — 4,534 Total liabilities $ 5,084 $ — $ 550 $ 4,534
Schedule of changes in fair value of Level 3 inputs	The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs: Six months ended (in millions) 2018 2017 Beginning balance $ 4,534 $ 4,213 Change in fair value recognized in net earnings 337 146 Milestone payments (50 ) — Ending balance $ 4,821 $ 4,359
Schedule of book values, approximate fair values and bases used to measure certain financial instruments	The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2018 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant observable Significant Liabilities Short-term borrowings $ 3,511 $ 3,508 $ — $ 3,508 $ — Current portion of long-term debt and lease obligations, excluding fair value hedges 3,026 3,026 998 2,028 — Long-term debt and lease obligations, excluding fair value hedges 31,216 30,750 30,675 75 — Total liabilities $ 37,753 $ 37,284 $ 31,673 $ 5,611 $ — The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2017 are shown in the table below: Basis of fair value measurement (in millions) Book value Approximate fair value Quoted prices in active markets for identical assets Significant observable Significant Assets Investments $ 48 $ 48 $ — $ — $ 48 Total assets $ 48 $ 48 $ — $ — $ 48 Liabilities Short-term borrowings $ 400 $ 400 $ — $ 400 $ — Current portion of long-term debt and lease obligations, excluding fair value hedges 6,023 6,034 4,004 2,030 — Long-term debt and lease obligations, excluding fair value hedges 31,346 32,846 32,763 83 — Total liabilities $ 37,769 $ 39,280 $ 36,767 $ 2,513 $ —
Summary of available-for-sale securities by type	The following table is a summary of available-for-sale securities by type as of June 30, 2018 : Amortized cost Gross unrealized Fair value (in millions) Gains Losses Asset backed securities $ 455 $ 1 $ (2 ) $ 454 Corporate debt securities 1,018 3 (3 ) 1,018 Other debt securities 78 — (1 ) 77 Total $ 1,551 $ 4 $ (6 ) $ 1,549 The following table is a summary of available-for-sale securities by type as of December 31, 2017 : Amortized cost Gross unrealized Fair value (in millions) Gains Losses Asset backed securities $ 930 $ 1 $ (3 ) $ 928 Corporate debt securities 1,451 4 (2 ) 1,453 Other debt securities 144 — (1 ) 143 Equity securities 4 2 (2 ) 4 Total $ 2,529 $ 7 $ (8 ) $ 2,528

Post-Employment Benefits (Table

Post-Employment Benefits (Tables)	6 Months Ended
Post-Employment Benefits (Tables)	Jun. 30, 2018
Postemployment Benefits [Abstract]
Summary of net periodic benefit costs	The following is a summary of net periodic benefit cost relating to the company’s defined benefit and other post-employment plans: Defined Other post- Three months ended Six months ended Three months ended Six months ended (in millions) 2018 2017 2018 2017 2018 2017 2018 2017 Service cost $ 72 $ 59 $ 144 $ 117 $ 5 $ 6 $ 13 $ 13 Interest cost 57 51 114 101 4 6 12 12 Expected return on plan assets (110 ) (95 ) (221 ) (190 ) — — — — Amortization of actuarial losses and prior service costs 39 27 76 53 (3 ) (1 ) 1 — Net periodic benefit cost $ 58 $ 42 $ 113 $ 81 $ 6 $ 11 $ 26 $ 25

Equity (Tables)

Equity (Tables)	6 Months Ended
Equity (Tables)	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
Summary of share-based compensation expense	Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows: Three months ended Six months ended (in millions) 2018 2017 2018 2017 Cost of products sold $ 12 $ 10 $ 16 $ 13 Research and development 35 33 107 97 Selling, general and administrative 38 33 153 107 Pre-tax compensation expense 85 76 276 217 Tax benefit 19 18 48 65 After-tax compensation expense $ 66 $ 58 $ 228 $ 152
Summary of quarterly cash dividends	The following table summarizes quarterly cash dividends declared during 2018 and 2017 : 2018 2017 Date Declared Payment Date Dividend Per Share Date Declared Payment Date Dividend Per Share 06/14/18 08/15/18 $ 0.96 10/27/17 02/15/18 $ 0.71 02/15/18 05/15/18 $ 0.96 09/08/17 11/15/17 $ 0.64 06/22/17 08/15/17 $ 0.64 02/16/17 05/15/17 $ 0.64
Summary of changes in balances of each component of accumulated other comprehensive loss	The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2017 : (in millions) Foreign Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2016 $ (1,435 ) $ 140 $ (1,513 ) $ 46 $ 176 $ (2,586 ) Other comprehensive income (loss) before reclassifications 419 (217 ) (25 ) 20 (129 ) 68 Net losses (gains) reclassified from accumulated other comprehensive loss — — 38 (10 ) (58 ) (30 ) Net current-period other comprehensive income (loss) 419 (217 ) 13 10 (187 ) 38 Balance as of June 30, 2017 $ (1,016 ) $ (77 ) $ (1,500 ) $ 56 $ (11 ) $ (2,548 ) The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2018 : (in millions) Foreign Net investment hedging activities Pension and post- Marketable security activities Cash flow hedging Total Balance as of December 31, 2017 $ (439 ) $ (203 ) $ (1,919 ) $ — $ (166 ) $ (2,727 ) Other comprehensive income (loss) before reclassifications (280 ) 105 9 (6 ) 110 (62 ) Net losses reclassified from accumulated other comprehensive loss — — 62 4 84 150 Net current-period other comprehensive income (loss) (280 ) 105 71 (2 ) 194 88 Balance as of June 30, 2018 $ (719 ) $ (98 ) $ (1,848 ) $ (2 ) $ 28 $ (2,639 )
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss	The table below presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss: Three months ended Six months ended (in millions) (brackets denote gains) 2018 2017 2018 2017 Pension and post-employment benefits Amortization of actuarial losses and other (a) $ 36 $ 26 $ 77 $ 53 Tax benefit (7 ) (7 ) (15 ) (15 ) Total reclassifications, net of tax $ 29 $ 19 $ 62 $ 38 Cash flow hedging activities Losses (gains) on designated cash flow hedges (b) $ 46 $ (46 ) $ 90 $ (63 ) Tax expense (benefit) (4 ) 4 (6 ) 5 Total reclassifications, net of tax $ 42 $ (42 ) $ 84 $ (58 ) (a) Amounts are included in the computation of net periodic benefit cost (see Note 10 ). (b) Amounts are included in cost of products sold (see Note 9 ).

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
Segment Information (Tables)	Jun. 30, 2018
Segment Reporting [Abstract]
Schedule of worldwide net revenues	AbbVie operates in one business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues: Three months ended Six months ended (in millions) 2018 2017 2018 2017 HUMIRA United States $ 3,521 $ 3,201 $ 6,524 $ 5,897 International 1,664 1,515 3,370 2,937 Total $ 5,185 $ 4,716 $ 9,894 $ 8,834 IMBRUVICA United States $ 693 $ 528 $ 1,317 $ 985 Collaboration revenues 157 98 295 192 Total $ 850 $ 626 $ 1,612 $ 1,177 HCV United States $ 422 $ 26 $ 765 $ 64 International 551 199 1,127 424 Total $ 973 $ 225 $ 1,892 $ 488 Creon United States $ 219 $ 196 $ 428 $ 381 Lupron United States $ 180 $ 172 $ 357 $ 327 International 43 38 85 77 Total $ 223 $ 210 $ 442 $ 404 Synthroid United States $ 193 $ 193 $ 375 $ 385 Synagis International $ 44 $ 40 $ 365 $ 340 AndroGel United States $ 128 $ 154 $ 258 $ 290 Duodopa United States $ 20 $ 14 $ 38 $ 28 International 88 67 173 133 Total $ 108 $ 81 $ 211 $ 161 Sevoflurane United States $ 19 $ 19 $ 36 $ 37 International 94 85 183 174 Total $ 113 $ 104 $ 219 $ 211 Kaletra United States $ 13 $ 19 $ 26 $ 38 International 78 91 138 187 Total $ 91 $ 110 $ 164 $ 225 All other $ 151 $ 289 $ 352 $ 586 Total net revenues $ 8,278 $ 6,944 $ 16,212 $ 13,482

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expenses and other	$ 2,729		$ 2,729			$ 4,741
Inventories	1,580		1,580			1,605
Accounts payable and accrued liabilities	10,694		10,694			10,226
Other long-term liabilities	15,543		15,543			15,605
Deferred income taxes	1,670		1,670			2,490
Retained earnings	5,495		5,495			$ 5,459
Net revenues	8,278	$ 6,944	16,212	$ 13,482
Cost of products sold	1,934	1,529	3,861	3,145
Income tax expense	29	438	43	813
Net earnings	$ 1,983	$ 1,915	$ 4,766	$ 3,626
Diluted earnings per share (in dollars per share)	$ 1.26	$ 1.19	$ 2.99	$ 2.25
Accounting Standards Update 2017-07 \| Operating earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of income		$ (12)		$ (24)
Accounting Standards Update 2017-07 \| Other (income) expense, net
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Reclassification of income		$ 12		$ 24
Non-operating income which would have been recorded in operating earnings under previous guidance	$ (14)		$ (18)
Difference between Revenue Guidance in Effect before and after Topic 606 \| Accounting Standards Update 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Prepaid expenses and other	101		101		$ 42
Inventories	(54)		(54)		(39)
Accounts payable and accrued liabilities	(46)		(46)		(57)
Other long-term liabilities	(46)		(46)		(75)
Deferred income taxes	16		16		22
Retained earnings	131		131		124
Net revenues	(13)		30
Cost of products sold	(5)		16
Income tax expense	0		7
Net earnings	$ (8)		$ 7
Diluted earnings per share (in dollars per share)	$ 0		$ 0
Calculated under Revenue Guidance in Effect before Topic 606 \| Accounting Standards Update 2014-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net revenues	$ 8,291		$ 16,182
Cost of products sold	1,939		3,845
Income tax expense	29		36
Net earnings	$ 1,991		$ 4,759
Diluted earnings per share (in dollars per share)	$ 1.26		$ 2.99
Retained earnings \| Accounting Standards Update 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment					(1,900)
Other assets \| Accounting Standards Update 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment					(500)
Prepaid expenses and other \| Accounting Standards Update 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment					$ (1,400)

Supplemental Financial Inform35

Supplemental Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Interest Expense, Net
Interest expense	$ 320	$ 284	$ 629	$ 557
Interest income	(48)	(31)	(106)	(57)
Interest expense, net	272	253	523	500
Inventories
Finished goods	465		465		$ 610
Work-in-process	924		924		822
Raw materials	191		191		173
Inventories	1,580		1,580		1,605
Property and Equipment
Property and equipment, gross	8,214		8,214		8,071
Accumulated depreciation	(5,427)		(5,427)		(5,268)
Property and equipment, net	2,787		2,787		$ 2,803
Depreciation expense	$ 119	$ 110	$ 234	$ 213

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Basic EPS
Net earnings	$ 1,983	$ 1,915	$ 4,766	$ 3,626
Earnings allocated to participating securities	10	9	22	18
Earnings available to common shareholders	$ 1,973	$ 1,906	$ 4,744	$ 3,608
Weighted-average basic shares outstanding (in shares)	1,568	1,595	1,579	1,595
Basic earnings per share (in dollars per share)	$ 1.26	$ 1.20	$ 3	$ 2.26
Diluted EPS
Net earnings	$ 1,983	$ 1,915	$ 4,766	$ 3,626
Earnings allocated to participating securities	10	9	22	18
Earnings available to common shareholders	$ 1,973	$ 1,906	$ 4,744	$ 3,608
Weighted-average basic shares outstanding (in shares)	1,568	1,595	1,579	1,595
Effect of dilutive securities (in shares)	4	5	5	7
Weighted-average diluted shares outstanding (in shares)	1,572	1,600	1,584	1,602
Diluted earnings per share (in dollars per share)	$ 1.26	$ 1.19	$ 2.99	$ 2.25

Licensing, Acquisitions, and 37

Licensing, Acquisitions, and Other Arrangements (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Collaborative and license agreements
Cash outflows related to acquisitions and investments				$ 401	$ 100
Acquired in-process research and development		$ 0	$ 15	69	15
Other expense		500	$ 0	$ 500	$ 0
Collaborative arrangement
Collaborative and license agreements
Additional contribution to collaboration	$ 500
Collaborative arrangement \| Calico Life Sciences Llc
Collaborative and license agreements
Additional contribution to collaboration by partner	$ 500
Term by which the agreement was extended	3 years
Other expense		$ 500

Collaboration with Janssen Bi38

Collaboration with Janssen Biotech, Inc. (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Collaborative and license agreements
Accounts receivable, net	$ 5,793		$ 5,793		$ 5,088
Accounts payable and accrued liabilities	10,694		$ 10,694		10,226
Collaborative arrangement
Collaborative and license agreements
Share of collaboration development costs responsible by the entity (as a percent)			40.00%
Global - AbbVie's share of other costs (included in respective line items)	80	$ 75	$ 151	$ 134
Collaborative arrangement \| International
Collaborative and license agreements
International - AbbVie's share of profits (included in net revenues)	157	98	295	192
Collaborative arrangement \| Janssen Biotech Inc [Member]
Collaborative and license agreements
Milestone payments	200		$ 200
Share of collaboration development costs responsible by Janssen (as a percent)			60.00%
Accounts receivable, net	167		$ 167		124
Accounts payable and accrued liabilities	310		310		$ 253
Collaborative arrangement \| Janssen Biotech Inc [Member] \| United States
Collaborative and license agreements
United States - Janssen's share of profits (included in cost of products sold)	$ 325	$ 247	$ 601	$ 459

Goodwill and Intangible Asset39

Goodwill and Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	6 Months Ended
	Jun. 30, 2018USD ($)
Goodwill
Goodwill, beginning balance	$ 15,785
Foreign currency translation adjustments	(93)
Goodwill, ending balance	$ 15,692

Goodwill and Intangible Asset40

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Accumulated goodwill impairment losses	$ 0		$ 0
Amortization of intangible assets	$ 324,000,000	$ 269,000,000	654,000,000	$ 540,000,000
Indefinite-lived intangible asset impairment charges			$ 0	$ 0

Goodwill and Intangible Asset41

Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Details) - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 23,698	$ 23,960
Accumulated amortization	(6,785)	(6,391)
Net carrying amount	16,913	17,569
Intangible assets
Indefinite-lived research and development	9,990	9,990
Net carrying amount - Indefinite-lived research and development	9,990	9,990
Total intangible assets gross carrying amount	33,688	33,950
Accumulated amortization - Total intangible assets	(6,785)	(6,391)
Total intangible assets, net	26,903	27,559
Developed product rights
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	15,873	16,138
Accumulated amortization	(5,169)	(4,982)
Net carrying amount	10,704	11,156
License agreements
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	7,825	7,822
Accumulated amortization	(1,616)	(1,409)
Net carrying amount	$ 6,209	$ 6,413

Restructuring Plans (Details)

Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
Restructuring Plans (Details) - USD ($) $ in Millions	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Restructuring reserve activity
Accrued balance beginning of the period			$ 86
Restructuring charges	$ 1	$ 11	23	$ 27
Payments and other adjustments			(21)
Accrued balance end of the period	$ 88		$ 88

Financial Instruments and Fai43

Financial Instruments and Fair Value Measures - Financial Instruments (Details)	6 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2018EUR (€)	May 17, 2018USD ($)	Dec. 31, 2017USD ($)
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes			$ 3,000,000,000
Foreign currency contracts in asset position	$ 143,000,000			$ 23,000,000
Foreign currency contracts in liability position	$ 684,000,000			550,000,000
Designated as hedging instrument \| Net Investment Hedges \| Senior notes
Derivative instruments, notional amount and fair value
Principal amount of unsecured senior notes		€ 3,600,000,000		3,600,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Duration of forward exchange contracts	18 months
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash Flow Hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	$ 2,300,000,000			2,200,000,000
Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold	6 months
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash Flow Hedges \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	$ 100,000,000			1,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash Flow Hedges \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	8,000,000			120,000,000
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash Flow Hedges \| Other assets
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	15,000,000			0
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash Flow Hedges \| Other long-term liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	0			0
Designated as hedging instrument \| Interest rate contracts \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	0			0
Designated as hedging instrument \| Interest rate contracts \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	7,000,000			8,000,000
Designated as hedging instrument \| Interest rate contracts \| Fair value hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	11,800,000,000			11,800,000,000
Designated as hedging instrument \| Interest rate contracts \| Fair value hedges \| Other assets
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	0			0
Designated as hedging instrument \| Interest rate contracts \| Fair value hedges \| Other long-term liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	637,000,000			393,000,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	11,300,000,000			7,700,000,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Foreign currency contracts in asset position	28,000,000			22,000,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Foreign currency contracts in liability position	$ 32,000,000			$ 29,000,000

Financial Instruments and Fai44

Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Fair value hedges \| Interest expense, net
Gain (loss) on derivatives
Debt designated as hedged item in fair value hedges gain (loss)	$ 59	$ (47)	$ 243	$ (32)
Senior notes \| Net Investment Hedges \| Designated as hedging instrument
Gain (loss) on derivatives
Recognized pre-tax gain (loss)	270	(239)	136	(339)
Foreign currency forward exchange contracts
Gain (loss) on derivatives
Gains (losses) recognized in other comprehensive income	169	(78)	121	(139)
Foreign currency forward exchange contracts \| Not designated as hedges \| Net foreign exchange loss
Gain (loss) on derivatives
Derivative gain (loss), net	128	(25)	69	(71)
Foreign currency forward exchange contracts \| Cash Flow Hedges
Gain (loss) on derivatives
Pretax unrealized losses	16		16
Foreign currency forward exchange contracts \| Cash Flow Hedges \| Designated as hedging instrument \| Cost of products sold
Gain (loss) on derivatives
Derivative gain (loss), net	(46)	46	(90)	63
Interest rate swaps designated as fair value hedges \| Fair value hedges \| Designated as hedging instrument \| Interest expense, net
Gain (loss) on derivatives
Derivative gain (loss), net	$ (59)	$ 47	$ (243)	$ 32

Financial Instruments and Fai45

Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Assets
Foreign currency contracts	$ 143	$ 23
Liabilities
Foreign currency contracts	$ 684	550
Changes Measurement \| Stemcentrx and BI \| Change In Assumed Discount Rate
Liabilities
Discount rate change	50.00%
Contingent consideration liability change	$ 180
Changes Measurement \| Stemcentrx and BI \| Change In Assumed Probability Rate
Liabilities
Contingent consideration liability change	$ 410
Assumed probability rate change	5.00%
Quoted prices in active markets for identical assets (Level 1)
Assets
Time deposits		0
Total assets		0
Liabilities
Total liabilities	$ 31,673	36,767
Significant other observable inputs (Level 2)
Assets
Time deposits		0
Total assets		0
Liabilities
Total liabilities	5,611	2,513
Significant unobservable inputs (Level 3)
Assets
Time deposits		48
Total assets		48
Liabilities
Total liabilities	0	0
Recurring
Assets
Cash and equivalents	3,547	9,303
Debt securities	1,549	2,524
Equity securities	9	4
Total assets	5,315	11,854
Liabilities
Interest rate hedges	644	401
Contingent consideration	4,821	4,534
Total liabilities	5,505	5,084
Recurring \| Foreign Currency Contract
Assets
Foreign currency contracts	143	23
Liabilities
Foreign currency contracts	40	149
Recurring \| Time deposits
Assets
Time deposits	67
Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	867	849
Debt securities	0	0
Equity securities	9	4
Total assets	876	853
Liabilities
Interest rate hedges	0	0
Contingent consideration	0	0
Total liabilities	0	0
Recurring \| Quoted prices in active markets for identical assets (Level 1) \| Foreign Currency Contract
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	0
Recurring \| Quoted prices in active markets for identical assets (Level 1) \| Time deposits
Assets
Time deposits	0
Recurring \| Significant other observable inputs (Level 2)
Assets
Cash and equivalents	2,680	8,454
Debt securities	1,549	2,524
Equity securities	0	0
Total assets	4,439	11,001
Liabilities
Interest rate hedges	644	401
Contingent consideration	0	0
Total liabilities	684	550
Recurring \| Significant other observable inputs (Level 2) \| Foreign Currency Contract
Assets
Foreign currency contracts	143	23
Liabilities
Foreign currency contracts	40	149
Recurring \| Significant other observable inputs (Level 2) \| Time deposits
Assets
Time deposits	67
Recurring \| Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	0	0
Debt securities	0	0
Equity securities	0	0
Total assets	0	0
Liabilities
Interest rate hedges	0	0
Contingent consideration	4,821	4,534
Total liabilities	4,821	4,534
Recurring \| Significant unobservable inputs (Level 3) \| Foreign Currency Contract
Assets
Foreign currency contracts	0	0
Liabilities
Foreign currency contracts	0	$ 0
Recurring \| Significant unobservable inputs (Level 3) \| Time deposits
Assets
Time deposits	$ 0

Financial Instruments and Fai46

Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Between The Fair Value Measurement Levels (Details) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Transfers of assets or liabilities between the fair value measurement levels
Transfer of assets from level 1 to level 2	$ 0
Transfer of assets from level 2 to level 1	0
Transfer of liabilities from level 1 to level 2	0
Transfer of liabilities from level 2 to level 1	0
Stemcentrx and BI
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Beginning balance	4,534,000,000	$ 4,213,000,000
Change in fair value recognized in net earnings	337,000,000	146,000,000
Milestone payments	(50,000,000)	0
Ending balance	$ 4,821,000,000	$ 4,359,000,000

Financial Instruments and Fai47

Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Liabilities
Carrying amount of investments in equity securities that do not have readily determinable fair values	$ 76
Quoted prices in active markets for identical assets (Level 1)
Assets
Investments		$ 0
Total assets		0
Liabilities
Short-term borrowings	0	0
Current portion of long-term debt and lease obligations, excluding fair value hedges	998	4,004
Long-term debt and lease obligations, excluding fair value hedges	30,675	32,763
Total liabilities	31,673	36,767
Significant other observable inputs (Level 2)
Assets
Investments		0
Total assets		0
Liabilities
Short-term borrowings	3,508	400
Current portion of long-term debt and lease obligations, excluding fair value hedges	2,028	2,030
Long-term debt and lease obligations, excluding fair value hedges	75	83
Total liabilities	5,611	2,513
Significant unobservable inputs (Level 3)
Assets
Investments		48
Total assets		48
Liabilities
Short-term borrowings	0	0
Current portion of long-term debt and lease obligations, excluding fair value hedges	0	0
Long-term debt and lease obligations, excluding fair value hedges	0	0
Total liabilities	0	0
Book value
Assets
Investments		48
Total assets		48
Liabilities
Short-term borrowings	3,511	400
Current portion of long-term debt and lease obligations, excluding fair value hedges	3,026	6,023
Long-term debt and lease obligations, excluding fair value hedges	31,216	31,346
Total liabilities	37,753	37,769
Approximate fair value
Assets
Investments		48
Total assets		48
Liabilities
Short-term borrowings	3,508	400
Current portion of long-term debt and lease obligations, excluding fair value hedges	3,026	6,034
Long-term debt and lease obligations, excluding fair value hedges	30,750	32,846
Total liabilities	$ 37,284	$ 39,280

Financial Instruments and Fai48

Financial Instruments and Fair Value Measures - Available-for-sale Securities (Details) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Available-for-sale Securities
Maximum maturity period of long-term debt securities (in years)	5 years
Amortized cost	$ 1,551,000,000	$ 2,529,000,000
Gross unrealized, Gains	4,000,000	7,000,000
Gross unrealized, Losses	(6,000,000)	(8,000,000)
Fair value	1,549,000,000	2,528,000,000
Other-than-temporary impairments	0
Short-term investments
Available-for-sale Securities
Debt securities	128,000,000	482,000,000
Asset backed securities
Available-for-sale Securities
Amortized cost	455,000,000	930,000,000
Gross unrealized, Gains	1,000,000	1,000,000
Gross unrealized, Losses	(2,000,000)	(3,000,000)
Fair value	454,000,000	928,000,000
Corporate debt securities
Available-for-sale Securities
Amortized cost	1,018,000,000	1,451,000,000
Gross unrealized, Gains	3,000,000	4,000,000
Gross unrealized, Losses	(3,000,000)	(2,000,000)
Fair value	1,018,000,000	1,453,000,000
Other debt securities
Available-for-sale Securities
Amortized cost	78,000,000	144,000,000
Gross unrealized, Gains	0	0
Gross unrealized, Losses	(1,000,000)	(1,000,000)
Fair value	$ 77,000,000	143,000,000
Equity Securities, Investment Summary [Member]
Available-for-sale Securities
Amortized cost		4,000,000
Gross unrealized, Gains		2,000,000
Gross unrealized, Losses		(2,000,000)
Fair value		$ 4,000,000

Financial Instruments and Fai49

Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) $ in Millions	6 Months Ended
	Jun. 30, 2018USD ($)wholesaler	Jun. 30, 2017	Dec. 31, 2017USD ($)
Concentration of Risk
Net governmental receivables outstanding	$ 5,793		$ 5,088
Accounts receivable, net
Concentration of Risk
Number of principal customers \| wholesaler	3
Accounts receivable, net \| Geographic Risk
Concentration of Risk
Concentrations risk (as a percent)	59.00%	56.00%
Total revenues \| HUMIRA
Concentration of Risk
Concentrations risk (as a percent)	61.00%	66.00%
Greece, Portugal, Italy, and Spain \| Geographic Risk
Concentration of Risk
Net governmental receivables outstanding	$ 286		255
Saudi Arabia \| Geographic Risk
Concentration of Risk
Net governmental receivables outstanding	162		149
Russia \| Geographic Risk
Concentration of Risk
Net governmental receivables outstanding	$ 75		$ 152

Financial Instruments and Fai50

Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) - USD ($)	May 17, 2018	May 31, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Debt Instrument
Short-term borrowings			$ 3,511,000,000	$ 400,000,000
Repayments of debt		$ 3,000,000,000
Principal amount of term loan	$ 3,000,000,000
Debt term	364 days
Commercial paper
Debt Instrument
Short-term borrowings			$ 511,000,000	$ 400,000,000
Weighted-average interest rate (as a percent)			1.90%		1.10%
Loans Payable [Member]
Debt Instrument
Short-term borrowings			$ 3,000,000,000
Senior notes \| Senior Notes Due In 2018 At 1.80 Percent
Debt Instrument
Stated interest rate (as a percent)			1.80%

Post-Employment Benefits (Detai

Post-Employment Benefits (Details) - AbbVie sponsored plans - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Defined benefit plans
Defined benefit and other post-employment plans
Service cost	$ 72	$ 59	$ 144	$ 117
Interest cost	57	51	114	101
Expected return on plan assets	(110)	(95)	(221)	(190)
Amortization of actuarial losses and prior service costs	39	27	76	53
Net periodic benefit cost	58	42	113	81
Other post-employment plans
Defined benefit and other post-employment plans
Service cost	5	6	13	13
Interest cost	4	6	12	12
Expected return on plan assets	0	0	0	0
Amortization of actuarial losses and prior service costs	(3)	(1)	1	0
Net periodic benefit cost	$ 6	$ 11	$ 26	$ 25

Equity - Stock-Based Compensati

Equity - Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 85	$ 76	$ 276	$ 217
Tax benefit	19	18	48	65
After-tax compensation expense	66	58	228	152
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	12	10	16	13
Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	35	33	107	97
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Pre-tax compensation expense	$ 38	$ 33	$ 153	$ 107

Equity - Stock Options (Details

Equity - Stock Options (Details) - Stock Options $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award
Stock options granted (in shares) \| shares	0.6
Weighted-average grant-date fair value of the stock options granted (in dollars per share) \| $ / shares	$ 21.63
Unrecognized compensation cost \| $	$ 11
Period for recognition of unrecognized compensation cost	2 years

Equity - RSAs, RSUs and Perform

Equity - RSAs, RSUs and Performance Shares (Details) $ / shares in Units, shares in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares
RSUs and Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award
Shares granted (in shares) \| shares	3.8
Fair market value of awards vested (in dollars per share) \| $ / shares	$ 114.69
RSAs, RSUs, and Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award
Unrecognized compensation cost \| $	$ 400
Period for recognition of unrecognized compensation cost	2 years

Equity - Cash Dividends (Detail

Equity - Cash Dividends (Details) - $ / shares	Jun. 14, 2018	Feb. 15, 2018	Oct. 27, 2017	Sep. 08, 2017	Jun. 22, 2017	Feb. 16, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Stockholders' Equity Note [Abstract]
Cash dividends declared per common share (in dollars per share)	$ 0.96	$ 0.96	$ 0.71	$ 0.64	$ 0.64	$ 0.64	$ 0.96	$ 0.64	$ 1.92	$ 1.28

Equity - Stock Repurchase Progr

Equity - Stock Repurchase Program (Details) - USD ($) $ / shares in Units, shares in Millions	Jun. 04, 2018	Jun. 30, 2018	Feb. 15, 2018
Stock Repurchase Program
Amount authorized under stock repurchase program			$ 10,000,000,000
Remaining stock repurchase authorization		$ 2,500,000,000
May 2018 Dutch Auction Tender Offer
Stock Repurchase Program
Stock repurchase amount	$ 7,500,000,000
Stock repurchased (in shares)	72.8
Dutch auction tender offer stock repurchase price (in dollars per share)	$ 103
Open Market Stock Repurchases
Stock Repurchase Program
Stock repurchase amount		$ 1,300,000,000
Stock repurchased (in shares)		10.9

Equity - Accumulated Other Comp

Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
AOCI Attributable to Parent, Net of Tax
AOCI, beginning balance			$ 5,097
Other comprehensive income (loss)	$ 9	$ 6	(88)	$ (38)
AOCI, ending balance	(3,375)		(3,375)
AOCI Attributable to Parent
AOCI Attributable to Parent, Net of Tax
AOCI, beginning balance			(2,727)	(2,586)
Other comprehensive income (loss) before reclassifications			(62)	68
Net losses reclassified from accumulated other comprehensive loss			150	(30)
Other comprehensive income (loss)			(88)	(38)
AOCI, ending balance	(2,639)	(2,548)	(2,639)	(2,548)
Foreign currency translation adjustments
AOCI Attributable to Parent, Net of Tax
AOCI, beginning balance			(439)	(1,435)
Other comprehensive income (loss) before reclassifications			(280)	419
Net losses reclassified from accumulated other comprehensive loss			0	0
Other comprehensive income (loss)			280	(419)
AOCI, ending balance	(719)	(1,016)	(719)	(1,016)
Net investment hedging activities
AOCI Attributable to Parent, Net of Tax
AOCI, beginning balance			(203)	140
Other comprehensive income (loss) before reclassifications			105	(217)
Net losses reclassified from accumulated other comprehensive loss			0	0
Other comprehensive income (loss)			(105)	217
AOCI, ending balance	(98)	(77)	(98)	(77)
Pension and post- employment benefits
AOCI Attributable to Parent, Net of Tax
AOCI, beginning balance			(1,919)	(1,513)
Other comprehensive income (loss) before reclassifications			9	(25)
Net losses reclassified from accumulated other comprehensive loss			62	38
Other comprehensive income (loss)			(71)	(13)
AOCI, ending balance	(1,848)	(1,500)	(1,848)	(1,500)
Marketable security activities
AOCI Attributable to Parent, Net of Tax
AOCI, beginning balance			0	46
Other comprehensive income (loss) before reclassifications			(6)	20
Net losses reclassified from accumulated other comprehensive loss			4	(10)
Other comprehensive income (loss)			2	(10)
AOCI, ending balance	(2)	56	(2)	56
Cash flow hedging activities
AOCI Attributable to Parent, Net of Tax
AOCI, beginning balance			(166)	176
Other comprehensive income (loss) before reclassifications			110	(129)
Net losses reclassified from accumulated other comprehensive loss			84	(58)
Other comprehensive income (loss)			(194)	187
AOCI, ending balance	$ 28	$ (11)	$ 28	$ (11)

Equity - Amounts Reclassified O

Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Pension and post- employment benefits
Significant amounts reclassified out of each component of AOCI
Reclassifications from accumulated other comprehensive income, before tax	$ 36	$ 26	$ 77	$ 53
Tax (benefit) expense	(7)	(7)	(15)	(15)
Reclassifications from accumulated other comprehensive income, after tax	29	19	62	38
Cash flow hedging activities
Significant amounts reclassified out of each component of AOCI
Reclassifications from accumulated other comprehensive income, before tax	46	(46)	90	(63)
Tax (benefit) expense	(4)	4	(6)	5
Reclassifications from accumulated other comprehensive income, after tax	$ 42	$ (42)	$ 84	$ (58)

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Effective tax rate	2.00%	19.00%	1.00%	18.00%
U.S. statutory tax rate			21.00%	35.00%
Tax Cuts and Jobs Act transition tax expense					$ 4,500,000,000
Tax Cuts and Jobs Act net tax benefit from the remeasurement of deferred taxes					$ 4,100,000,000
Tax Cuts and Jobs Act adjustments to provisional estimates	$ 0		$ 0
Potential change in unrecognized tax benefits	$ 272,000,000		$ 272,000,000

Legal Proceedings and Conting60

Legal Proceedings and Contingencies (Details)	1 Months Ended							6 Months Ended
Legal Proceedings and Contingencies (Details)	Jun. 30, 2018USD ($)claim	Mar. 31, 2018USD ($)	Oct. 31, 2017USD ($)	Jul. 31, 2017USD ($)	Jun. 30, 2016investment_fund	Nov. 30, 2014individual	Sep. 30, 2014company	Jun. 30, 2018USD ($)claim	Jun. 30, 2018USD ($)claimdirect_purchaser	Jun. 30, 2018USD ($)claimlawsuit	Jun. 30, 2018USD ($)claimcompany	Jun. 30, 2018USD ($)claimclass_action	Jun. 30, 2018USD ($)claimend_payor_purchaser	Dec. 31, 2017USD ($)
Legal Proceedings and Contingencies
Recorded accrual balance for litigation	$ 560,000,000							$ 560,000,000	$ 560,000,000	$ 560,000,000	$ 560,000,000	$ 560,000,000	$ 560,000,000	$ 445,000,000
Number of individual putative class action lawsuit					5	5
Depakote
Legal Proceedings and Contingencies
Number of claims pending \| claim	596							596	596	596	596	596	596
Percentage of pending claims in US District Courts								90.00%
AndroGel Antitrust Litigation
Legal Proceedings and Contingencies
Recorded accrual balance for litigation	$ 0							$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Number of generic companies with whom certain litigation related agreements were entered into \| company											3
Number of individual plaintiff lawsuits \| lawsuit										4
Number of purported class actions \| class_action												3
AndroGel Antitrust Litigation \| Allegation of proposed generic products infringing AbbVie's patents and seeking declaratory and injunctive relief
Legal Proceedings and Contingencies
Number of generic companies with whom certain litigation related agreements were entered into \| company							2
AndroGel Antitrust Litigation \| Disgorgement remedy
Legal Proceedings and Contingencies
Damages awarded against company	$ 448,000,000
Niaspan
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits \| lawsuit										4
Number of purported class actions \| class_action												2
Number of healthcare benefit providers who filed lawsuits									3				10
Testosterone Replacement Therapy Products Liability Litigation
Legal Proceedings and Contingencies
Numbers of claims are consolidated for pre-trial purposes \| claim	4,130							4,130	4,130	4,130	4,130	4,130	4,130
Number of claims pending \| claim	200							200	200	200	200	200	200
Testosterone Replacement Therapy Products Liability Litigation \| Punitive damages
Legal Proceedings and Contingencies
Damages awarded against company		$ 3,000,000	$ 140,000,000	$ 150,000,000
Testosterone Replacement Therapy Products Liability Litigation \| Compensatory damages
Legal Proceedings and Contingencies
Damages awarded against company		$ 200,000	$ 140,000	$ 0

Segment Information Additional

Segment Information Additional Information (Details)	6 Months Ended
Segment Information Additional Information (Details)	Jun. 30, 2018segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment Information Disaggregat

Segment Information Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Total net revenues	$ 8,278	$ 6,944	$ 16,212	$ 13,482
HUMIRA
Disaggregation of Revenue [Line Items]
Total net revenues	5,185	4,716	9,894	8,834
HUMIRA \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	3,521	3,201	6,524	5,897
HUMIRA \| International
Disaggregation of Revenue [Line Items]
Total net revenues	1,664	1,515	3,370	2,937
IMBRUVICA
Disaggregation of Revenue [Line Items]
Total net revenues	850	626	1,612	1,177
IMBRUVICA \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	693	528	1,317	985
IMBRUVICA \| International \| Collaborative arrangement
Disaggregation of Revenue [Line Items]
Total net revenues	157	98	295	192
HCV
Disaggregation of Revenue [Line Items]
Total net revenues	973	225	1,892	488
HCV \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	422	26	765	64
HCV \| International
Disaggregation of Revenue [Line Items]
Total net revenues	551	199	1,127	424
Lupron
Disaggregation of Revenue [Line Items]
Total net revenues	223	210	442	404
Lupron \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	180	172	357	327
Lupron \| International
Disaggregation of Revenue [Line Items]
Total net revenues	43	38	85	77
Creon \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	219	196	428	381
Synagis \| International
Disaggregation of Revenue [Line Items]
Total net revenues	44	40	365	340
Synthroid \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	193	193	375	385
AndroGel \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	128	154	258	290
Kaletra
Disaggregation of Revenue [Line Items]
Total net revenues	91	110	164	225
Kaletra \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	13	19	26	38
Kaletra \| International
Disaggregation of Revenue [Line Items]
Total net revenues	78	91	138	187
Sevoflurane
Disaggregation of Revenue [Line Items]
Total net revenues	113	104	219	211
Sevoflurane \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	19	19	36	37
Sevoflurane \| International
Disaggregation of Revenue [Line Items]
Total net revenues	94	85	183	174
Duodopa
Disaggregation of Revenue [Line Items]
Total net revenues	108	81	211	161
Duodopa \| United States
Disaggregation of Revenue [Line Items]
Total net revenues	20	14	38	28
Duodopa \| International
Disaggregation of Revenue [Line Items]
Total net revenues	88	67	173	133
All other
Disaggregation of Revenue [Line Items]
Total net revenues	$ 151	$ 289	$ 352	$ 586